Ayvakit Sprinkle
(Avutometinib)Phase 2Small molecule
This medication combines two drugs that block abnormal proteins in cancer cells, helping to stop or slow the growth and spread of a specific type of ovarian cancer.[1] Ayvakit Sprinkle is currently being investigated across 10 indications[3], with its most advanced program in Phase 2.[1]
Ayvakit Sprinkle is one of 289 small molecule programs targeting Cutaneous Melanoma. It is currently in Phase 2.
10
Indications
15
Total Trials
14
Active Trials
288
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Phase 2
Yervoy
Bristol-Myers SquibbPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
PORTRAZZA
Eli LillyPreclinical
Imjudo
AstraZenecaPreclinical
Vizimpro
PfizerPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ovarian Cancer3 trials
Non-Small Cell Lung Cancer2 trials
Avutometinib2 trials
Colorectal Cancer1 trial
6 more indications
Gastric Cancer1 trial
Avutometinib and Defactinib in Diffuse Gastric Cancer
Recruiting·—·Phase 2·NCT06487221·27 enrolled
Pancreatic Adenocarcinoma1 trial
Gynecologic Cancer1 trial
Cutaneous Melanoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Avutometinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details